Skip to main content
. 2022 Jan 24;12(3):368. doi: 10.3390/nano12030368

Figure 9.

Figure 9

Alterations in CREBp-1, AMPK protein (a), metabolic intermediates beta-hydroxybutyrate (b) and acetoacetate (c) levels in vehicle control, NLCs-KAA, NLCs-PUNI-KAA and PUNI and orlistat treated maturing adipocyte after 14 days. Each of the values are means ± SD (n = 6). Significance levels are represented as ** p ≤ 0.001 and * p ≤ 0.05 compared with vehicle control.